Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study
Authors:ID Hochmair, Maximilian J (Author)
ID Morabito, Alessandro (Author)
ID Hao, Desiree (Author)
ID Yang, Cheng-Ta (Author)
ID Soo, Ross A (Author)
ID Yang, James C-H (Author)
ID Gucalp, Rasim (Author)
ID Halmos, Balazs (Author)
ID Wang, Lara (Author)
ID Golembesky, Amanda (Author)
ID Märten, Angela (Author)
ID Čufer, Tanja, Klinika Golnik, Medicinska fakulteta UL (Author)
Files:.pdf PDF - Presentation file, download (2,39 MB)
MD5: 3F2D8BA9D4F2488B02256DB856ABFA69
 
URL URL - Source URL, visit https://www.futuremedicine.com/doi/full/10.2217/fon-2018-0711?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed#
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Materials & methods: In this retrospective, observational, multicenter study, patients (n = 204) had T790M-positive disease following first-line afatinib and started osimertinib treatment [>/=]10 months prior to data entry. Primary outcome was time on treatment. Results: Overall median time on treatment was 27.6 months (90% CI: 25.9-31.3), 30.3 months (90% CI: 27.6-44.5) in Del19-positive patients and 46.7 months (90% CI: 26.8-not reached) in Asians. The 2-year overall survival was 78.9%. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib facilitates prolonged, chemotherapy-free treatment in patients with T790M acquired resistance, and is a potentially attractive strategy, especially for Del19-positive tumors.
Keywords:lung neoplasms -- therapy, non-small-cell lung cancer, afatinib, osimertinib, epidermal growth factor receptor, EGFR, observational study
Publication status:Published
Publication version:Version of Record
Place of publishing:Velika Britanija
Publisher:Future Medicine Ltd
Year of publishing:2018
Number of pages:str. 2861-2874
Numbering:Vol. 14, no. 27
PID:20.500.12556/DiRROS-12623 New window
UDC:616-006
ISSN on article:1744-8301
DOI:10.2217/fon-2018-0711 New window
COBISS.SI-ID:2048432753 New window
Copyright:2018 Maximilian Hochmair
Note:Soavtorji: Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Amanda Golembesky, Angela Märten & Tanja Cufer; Nasl. z nasl. zaslona; Opis vira z dne 9. 1. 2019;
Publication date in DiRROS:09.11.2020
Views:2103
Downloads:1179
Metadata:XML DC-XML DC-RDF
:
HOCHMAIR, Maximilian J, MORABITO, Alessandro, HAO, Desiree, YANG, Cheng-Ta, SOO, Ross A, YANG, James C-H, GUCALP, Rasim, HALMOS, Balazs, WANG, Lara, GOLEMBESKY, Amanda, MÄRTEN, Angela and ČUFER, Tanja, 2018, Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : an observational study. Future oncology [online]. 2018. Vol. 14, no. 27, p. 2861–2874. [Accessed 23 March 2025]. DOI 10.2217/fon-2018-0711. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=12623
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Future oncology
Publisher:Future Medicine
ISSN:1744-8301
COBISS.SI-ID:521824025 New window

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:19.10.2018

Secondary language

Language:Undetermined
Keywords:pljučne novotvorbe -- terapija, nedrobnocelični pljučni rak, afatinib, osimertinib, receptor za epidermalni rastni dejavnik, EGFR, opazovalna raziskava


Back